Integer (NYSE:ITGR) Stock Rating Lowered by Freedom Capital

Integer (NYSE:ITGR) was downgraded by equities researchers at Freedom Capital from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other analysts have also recently weighed in on the stock. Truist Financial cut shares of Integer from a “buy” rating to a “hold” rating and raised their price target for the company from $110.00 to $127.00 in a report on Monday. Wells Fargo & Company boosted their price objective on shares of Integer from $84.00 to $127.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Raymond James Financial lowered shares of Integer from a “moderate buy” rating to a “hold” rating in a report on Monday. Zacks Research raised Integer from a “strong sell” rating to a “hold” rating in a research report on Monday, July 20th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Integer presently has a consensus rating of “Hold” and an average price target of $109.86.

Integer Stock Performance

Shares of ITGR stock opened at $124.94 on Tuesday. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of 31.16, a PEG ratio of 2.97 and a beta of 0.61. Integer has a 52-week low of $62.00 and a 52-week high of $125.54. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77. The company’s 50 day moving average is $95.27 and its 200 day moving average is $89.56.

Integer (NYSE:ITGR) last posted its earnings results on Monday, August 3rd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.38 by $0.22. The company had revenue of $464.11 million during the quarter, compared to analyst estimates of $451.07 million. Integer had a return on equity of 12.77% and a net margin of 6.97%.Integer’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.55 earnings per share. On average, sell-side analysts anticipate that Integer will post 6.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Integer

Hedge funds have recently made changes to their positions in the company. Irenic Capital Management LP purchased a new position in Integer in the 4th quarter worth $99,109,000. Alliancebernstein L.P. lifted its holdings in shares of Integer by 885.1% during the second quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock worth $136,016,000 after purchasing an additional 993,810 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Integer by 1,141.6% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 819,046 shares of the medical equipment provider’s stock worth $72,076,000 after buying an additional 753,081 shares during the period. Millennium Management LLC lifted its stake in Integer by 3,350.2% during the 4th quarter. Millennium Management LLC now owns 677,108 shares of the medical equipment provider’s stock valued at $53,106,000 after acquiring an additional 657,483 shares during the period. Finally, J. Goldman & Co LP purchased a new position in shares of Integer during the fourth quarter worth $40,531,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer News Roundup

Here are the key news stories impacting Integer this week:

• Positive Sentiment: KKR agreed to acquire Integer in an all-cash transaction valued at approximately $5.7 billion. Stockholders would receive $127 per share, representing a 51.8% premium to the price before Integer announced its strategic review and a 28.8% premium to the 30-day volume-weighted average price. The deal is expected to close by year-end 2026, subject to shareholder and regulatory approvals. Integer to Be Acquired by KKR
• Positive Sentiment: KKR’s backing is expected to give Integer additional capital and flexibility to invest in manufacturing capacity, technology, innovation and talent. The private-equity firm also plans an employee ownership program, potentially supporting retention and productivity. Integer Holdings KKR Deal
• Positive Sentiment: Integer’s second-quarter results exceeded expectations: adjusted earnings were $1.60 per share versus the $1.38 consensus estimate, while revenue of $464.1 million topped the $450.7 million estimate. Earnings also improved from $1.55 per share a year earlier. Integer Second Quarter 2026 Results
• Neutral Sentiment: Wells Fargo raised its price target from $84 to $127 but maintained an “equal weight” rating, leaving little implied upside beyond the proposed transaction price. Wells Fargo Price Target Update
• Negative Sentiment: Truist downgraded Integer from “strong buy” to “hold,” reflecting the stock’s proximity to the $127 offer and limited potential upside if the deal closes. Truist Downgrade
• Negative Sentiment: Revenue declined 2.6% year over year, and Integer withdrew its financial outlook and canceled its planned earnings call because of the pending acquisition. Several law firms are also investigating whether shareholders are receiving a fair price, creating potential deal-related uncertainty. Shareholder Investigation

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.